{"disease":{"id":"fallopian-tube-carcinoma","name":"fallopian tube carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT01139957","title":"Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1916,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00951496","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1560,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03602859","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT00108745","title":"Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1157,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT00719303","title":"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1070,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT00565851","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1052,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06580314","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01167712","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":692,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04229615","title":"A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":690,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05460000","title":"A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":640,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT00954174","title":"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":637,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT03296826","title":"Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","has_results":false},{"nct_id":"NCT07269574","title":"Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT02502266","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":582,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04575935","title":"Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02446600","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":579,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04111978","title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Swiss GO Trial Group","has_results":false},{"nct_id":"NCT05737303","title":"Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":538,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT03150121","title":"Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT06915025","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Imunon","has_results":false},{"nct_id":"NCT00958698","title":"Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":485,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT04095364","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02839707","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":444,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00989651","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05043402","title":"A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"OncXerna Theraputics, Inc.","has_results":false},{"nct_id":"NCT06972693","title":"NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":323,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03373058","title":"Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":310,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03604315","title":"Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03180177","title":"Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":263,"lead_sponsor_name":"Shu-Zhong Cui","has_results":false},{"nct_id":"NCT03921658","title":"The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05537844","title":"Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Liz-Anne Lewsley","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06710548","title":"REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06274541","title":"Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Cancer Trials Ireland","has_results":false},{"nct_id":"NCT01091428","title":"Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02315469","title":"Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03776812","title":"Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Corcept Therapeutics","has_results":true},{"nct_id":"NCT01478685","title":"A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT05554328","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":165,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}